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Abstract: The latest development of protein engineering allows the production of proteins 
having desired properties and large potential markets, but the clinical advances of therapeutical 
proteins are still limited by their fragility. Nanotechnology could provide optimal vectors able to 
protect from degradation therapeutical biomolecules such as proteins, enzymes or specific poly-
peptides. On the other hand, some proteins can be also used as active ligands to help nanoparticles 
loaded with chemotherapeutic or other drugs to reach particular sites in the body. The aim of this 
review is to provide an overall picture of the general aspects of the most successful approaches 
used to combine proteins with nanosystems. This combination is mainly achieved by absorption, 
bioconjugation and encapsulation. Interactions of nanoparticles with biomolecules and caveats 
related to protein denaturation are also pointed out. A clear understanding of nanoparticle-protein 
interactions could make possible the design of precise and versatile hybrid nanosystems. This 
could further allow control of their pharmacokinetics as well as activity, and safety.
Keywords: nanoparticles, drug delivery, proteins, polypeptides, absorption, bioconjugation, 
encapsulation
Introduction and background
Nanotechnology has the potential to create new materials and devices with wide-ranging 
applications in medicine,1–3 agriculture,4 and energy or electronic production.5,6
The size-dependent optical, electrical, and magnetic properties of nanoparticles 
make nanotechnology a promising candidate for bioapplications such as in vivo 
imaging, sensing, catalysis, therapeutics, and cell targeting.7–9
Based on different approaches, physicians, physicists, chemists, biologists as well as 
bioengineers share a common interest to treat severe diseases through nanotechnology. 
Theoretically, nanoparticles can be tailored to reach the right target at the right time. 
Pathogenic agents such as viruses or bacteria, and cancer cells could be precisely 
targeted and affected without disturbing healthy tissues. This crucial task has been 
one of the highest priorities for the past 10 years.
Among several medical applications, nanoparticles could be largely employed 
as carriers of therapeutical biomolecules.10 The combination of nanoparticles with 
biomolecules such as proteins or specific polypeptides offers opportunities for the 
design of very precise and versatile hybrid systems mostly useful in helping to fight 
cancer and immunological diseases.11–13
There are more than 50,000 different proteins in the human body.14 Proteins are 
present in complex biological processes such as muscle contraction, immune protection 
and transmission of nerve impulses. All enzymes and most hormones are proteins; International Journal of Nanomedicine 2010:5 38
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hence, proteins are vital sources for the body’s metabolism 
and their lack can result in several diseases (eg, lack of insulin 
in type 1 diabetes).
The latest development of protein engineering allows 
the production of proteins having desired properties and 
great potential market;15 however, protein fragility is one of 
the major drawbacks for their utilization. Consequently, the 
discovery and development of new therapeutic proteins have 
also created new opportunities for drug-delivery systems 
involving the design of appropriate nanocarriers such as 
liposomes, micro-, and nanoparticles.16–19
The oral route is a comfortable way for drug administration 
especially when repeated or routine dosing is necessary.20 
Nevertheless, the development of oral carriers for many 
proteins remains a challenge due to the fact that bioavailability 
of these molecules is limited.21 Indeed, most polypeptides and 
proteins are quickly degraded in the gastrointestinal (GI) 
tract by proteolytic enzymes.22,23 Moreover, the intestinal 
epithelium is a major barrier to the absorption of hydrophilic 
drugs that cannot easily diffuse across the cells through the 
lipid-bilayer cell membranes.
Numerous investigations have shown that nanocarriers 
can improve the stability of therapeutic agents against 
enzymatic degradation and achieve desired therapeutic 
levels in target tissues for the required duration. Nanoparticle 
drug-delivery systems (nano-DDS) could permit an optimal 
pharmacokinetic profile and meet specific needs. For 
example, nanoparticles as oral protein carriers could protect 
the active ingredient in the GI tract and/or prolong the 
residence time of its contents on the mucous membrane. After 
administration, nano-DDS can be taken up and transported 
across the intestinal mucosa by enterocytes or M cells in 
the Peyer’s patches because of their small size.24
Several articles and reviews on the use of nanoparticles 
or microparticles for oral drug delivery are dedicated to 
insulin.25–28 In 1980, Couvreur and colleagues performed the 
first study on hypoglycemic effects after oral and parenteral 
administration of insulin-loaded nanoparticles to diabetic 
rats.26
Proteins are also difficult to be delivered via topical 
or transdermal routes and therefore their parenteral 
administration is still largely applied.
Besides the general complications of the parenteral route 
(such as local infections, thrombophlebitis, rarely tissue 
necrosis), small proteins (30 kD) are quickly filtered out 
by the kidneys. Without an appropriate drug carrier, proteins 
can also cause unwanted allergic reactions, can be targeted 
by the immune system and be rapidly degraded.
For example, rapid clearance from the circulation can be 
an explanation of the modest in vivo antitumor effects of the 
antiangiogenic RGD (Arg–Gly–Asp) peptides.29
Bone morphogenetic proteins (BMPs) induce bone 
formation after implantation; their orthopedic application 
in repair of bone fractures and defects is focused in local 
device and spinal fusion procedures. The problem of BMP is 
its rapid diffusion from the administration site when applied 
without a carrier. Currently, one of the most effective and 
biocompatible carriers for BMP delivery is the type I bovine 
absorbable collagen sponge (ACS). However the BMP 
release rate is difficult to control and to maintain constant for 
long term because of a high initial burst release of this device. 
The use of new nanotechnologies could maintain BMPs at 
the treatment site preventing extraneous bond formation and 
optimizing the drug release.30
Synthetic antigenic peptides are specific sections or a variant 
sequence of viral/bacterial proteins able to induce an immune 
response in the host. These small peptides are very useful in 
the vaccine development compared to the use of the whole 
protein/antigen. To date, several antigenic peptides have been 
identified but delivery problems still limit their application. 
Even in this case, the design of an effective delivery system 
is an important challenge in nanotechnology field.
An efficient protein carrier should solve different 
problems allowing the access to the target sites, at the right 
time and for the proper duration. In order to choose the best 
nanosystem, five factors must be considered: nature of the 
protein, route of administration, pattern of drug release, 
method of delivery and formulation.31,32
Proteins such as albumin, antibody, growth factors, 
transferrin, cytokines and low-density lipoprotein can be 
also used as active ligands to help nanoparticles loaded with 
chemotherapeutic or other drugs to reach particular sites in 
the body.33–35 Abraxane® (Abraxis Bioscience, Los Angeles, 
CA; AstraZeneca, Wilmington, DE), albumin–bound 
nanoparticle of paclitaxel, is an example of US Food and 
Drug Administration (FDA)-approved protein-based active 
ligand for the treatment of metastatic breast cancer.35
Monoclonal antibodies (mAb) has been widely used as 
bioprobes in diagnostics as well as delivery drug to specific 
tumors.36,37 OX26 mAb can help nanoparticles to cross the 
blood–brain barrier and diffuse in the brain tissue in order to 
transport drugs (eg, the anticaptase peptide, Z-DEVD-FMK) 
for the treatment of neurological and psychiatric disorders.38 
Nanoparticles can be also coated with mAb for cell surface 
antigen and used as a bait for detection or isolation of various 
kind of cells including lymphocyte and tumor cells.39,40International Journal of Nanomedicine 2010:5 39
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Despite many potential applications, the interaction of 
nanoparticles with biomolecules and living systems is still 
not fully understood.41–50 Continuous study on this subject 
contributes to the current knowledge and stimulates the 
development of novel therapies such as nonviral vectors 
for gene therapies or as precise anticancer molecules.37,51–53 
Furthermore, by clarifying these aspects, specific protein-
based nanovectors with optimized functions could be 
developed. This review aims to provide an overall picture 
on current progress and general aspect of the most successful 
approaches used to combine proteins with nanosystems. This 
combination is mainly achieved by absorption, bioconjugation 
or strong binding via avidin–biotin technology and 
encapsulation. These methods and the correlated problems 
of protein denaturation are discussed in turn in this review.
Nanoparticle–protein absorption, 
bioconjugation, and encapsulation
Absorption of proteins on nanoparticles 
surface
The interaction between biological and synthetic materials 
impacts on a vast range of medical issues from implants to 
pharmacokinetic aspects. The study of the materials bio-
compatibility starts, therefore, with the analysis of protein 
absorption on surfaces.54 Synthetic materials for biomedical 
applications are immediately covered by proteins when 
put in contact with a biological environment.55,56 After 
protein binding, nanoparticles are quickly cleared by the 
mononuclear phagocytic system (MPS), also known as the 
reticuloendothelial system (RES).57,58 These macrophages, 
which are typically Kupffer cells of the liver, cannot 
directly identify the nanoparticles themselves, but rather 
recognize specific opsonin proteins bound to the surface of 
the particles.59
The interaction between proteins and nanoparticles 
surface leads to the formation of proteins “corona” around 
nanoparticles that largely defines their biological identity as 
well their potential toxicity.49,50,58,60–64 Recently, Lynch and 
Dawson postulated the importance of the “protein corona” 
as the vehicle and the biological identity of a nanoparticle 
for its transport through cell membranes.60
The nanoparticle surface is immediately occupied by 
proteins with high concentrations and high association 
rate constants and successively by proteins having lower 
concentrations but a higher affinity.47 Competitive absorption 
of proteins is influenced by several factors such as electrostatic 
interactions, protein stability, and kinetic parameters.65
As the protein corona could affect the nanoparticle 
behavior, including its biological effect, the nanoparticle could 
also have an effect on the protein behavior. Some nanoparticles 
seem able to promote the protein assembly into amyloid fibrils 
in vitro by assisting the nucleation process.66 Bellezza and 
colleagues found that nanoparticles affect the morphology 
of the myoglobin absorbed onto phosphate-grafted zirconia 
nanoparticles, inducing prefibrillar-like aggregates.67 This 
phenomenon could have important implications for medical 
application of nanoparticles because the self-assembly of a 
variety of proteins and peptides is known to be the cause of 
human amyloid diseases where fibrous protein aggregates are 
formed, resulting in amyloid plaque deposition in the extra-
cellular tissues.68–74 Moreover, fibrillar structure seems to be 
related to heavy human disorders such as Alzheimer’s disease, 
Parkinson’s disease, and spongiform encephalopathies.
However this action seems strictly related to the type of 
nanosystems chosen. For instance, there are nanosystems 
such as C60 hydrated fullerenes that can relax fibrillar 
structures.60,68 Certainly, the control of the protein absorption 
on nanoparticle surfaces is an important issue to control their 
fate in biological systems.75
In order to prevent or control the opsonization, several 
methods of disguising nanoparticles have been developed. 
In these methods, generally, nanoparticles are coated with 
biocompatible polymers that have the double function 
of preventing their aggregation and retarding the protein 
absorption.57,76,77
A common strategy to improve blood compatibility and 
to increase the blood circulation half-life of the nanoparticles 
is the construction of a protein-coated surface resistant 
to the absorption of the other opsonines.78 A thin layer of 
protein appears to minimize adhesion and aggregation of 
nanoparticles, avoiding subsequent macrophage recognition 
or, in the worst case, a thrombus formation. Moreover, it is 
possible to properly tune the cells uptake of the nanoparticles 
using specific proteins.35
Proteins are mainly amphiphatic molecules that typically 
adhere to the surface of a biomaterial in a nonspecific way. 
In various cases, this nonspecific adhesion is sufficient to 
artificially immobilize proteins on the nanoparticles surface, 
and no surface modification is necessary.
Despite of the large number of studies, the absorption of a 
protein on whatever the solid surface is still a complex and not 
well understood process.60,79–85 In the case of nanoparticles, 
size and radius of curvature become significant when 
compared to the protein size resulting in new interactions 
not shown with the bulk materials.47International Journal of Nanomedicine 2010:5 40
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The high hydrophobicity of many proteins seems to play 
an important role in their absorption on the nanoparticles 
surface.86 Several models of protein absorption on surfaces 
identify two main steps in the process. The first step could 
involve the arrival of the protein at the interface, through a 
diffusion process following the Brownian law of motion, and 
its further collision with the solid surface. Depending on the 
balance of the energetic interaction, proteins can remain on 
the solid surface or return to solution. If the protein has been 
absorbed, the second step could lead to conformational changes 
(because of van der Waals interactions), surface charge, 
protein dipole moment, and protein size or solution ionic 
strength.84,85,87–90 This second step often involves irreversible 
changes in the protein structure up to denaturation.91–93
Proteins can be divided in two groups: hard and soft 
proteins. The first group includes proteins with high internal 
stability, while proteins in the second group have a low 
internal stability. Soft proteins seem to be able to change their 
conformation better than the hard ones. This characteristic 
results in a gain in conformational entropy when absorbed 
on solid surfaces, improving the efficacy of the absorption 
process when compared to the hard proteins. On the other 
hand, it seems that some degree of denaturation upon 
absorption is more probable for soft proteins than for the 
hard ones, especially on hydrophobic surfaces.84,94–97
During the artificial absorption of protein to nanoparticles 
surface, the use of a large excess of the target material could 
allow the retention of sufficient biological activity and native 
epitopes, even if some proteins are denatured. However, 
problems associated with denaturation of the protein over 
time, or its exchange with other proteins in solution, could 
make this strategy satisfactory only for short-term uses.
The success of an absorption strategy to deliver drug or 
therapeutical proteins using protein-based nanoparticles as a 
carrier can be influenced by several factors such as the type 
of nanoparticles, delivery route and the nature of proteins to 
be absorbed. For this reason, nanoparticle–protein affinity 
needs to be intensely examined case-by-case.
The knowledge of how the protein-based nanoparticles 
interact with other proteins present in the blood is fundamental 
for the understanding of their biological and toxicological 
properties.77 Many methods based on established techniques 
could be applied such as size-exclusion chromatography, 
isothermal  titration  calorimetry,  surface  plasmon 
resonance, atomic force microscopy, differential scanning 
calorimeter, and circular dichroisim (CD) spectroscopy.47,67
Even if several existing characterization methods for 
measuring the nature and the amount of absorbed protein on 
solid surfaces could be applied to nanoparticle systems,96 the 
development of new physical and biophysical methods may 
be necessary to fully understand the relationship between 
proteins and nanomaterials.
Bioconjugation of proteins  
on nanoparticle surfaces
Conjugation of biomolecules on nanoparticle surfaces 
has attracted widespread interest in biotechnology and 
medicine.7,98–100 The conjugation of specific proteins 
with nanoparticles has introduced a new advancement in 
molecular and cellular biology which has further led to a vast 
improvement of in vivo gene delivery, clinical diagnosis, 
medical/cancer imaging, receptor-targeted delivery.40,101–105
A preferred method used in many areas of biochemistry to 
couple specific protein to solid surface is the bioconjugation 
by covalent binding. While protein absorption on solid 
surfaces such as nanoparticles can be reversible depending 
on pH, salt concentration, temperature or other environment 
physicochemical characteristics, protein covalent bounds 
are highly stable. To fulfill the purpose of stable covalent 
binding, a large number of reactions have been proposed 
and many protein modifications using new techniques have 
been developed.7,106–111
The choice of the bioconjugation procedure depends 
strictly on physicochemical and biochemical properties of 
nanomaterials and proteins. Protein made by various side 
chains and residues can interact by multiple coating ligands 
with the same nanoparticles or even with more nanoparticles. 
Moreover, nanoparticles can be more or less polydispersed 
and have different physicochemical surface properties such as 
area, porosity, and charge. These aspects are very important 
since the hydrophobicity, charge and site affinity could 
affect the interaction and thus jeopardize the stability of final 
covalent-coupled products.
The most popular approach for coupling covalently 
nanoparticle to protein is based on the existence on proteins 
of specific and reactive functional groups such as amino–NH2 
(lysine), carboxylic acid–COOH (aspartic, glutamic), 
hydroxyl–OH (serine, tyrosine) and –SH (cysteine).112
Proteins can be chemically coupled to different kinds of 
nanoparticles using established reagents such bifunctional 
cross-linker molecules. In this case, nanoparticles need to 
be functionalized with functional groups such as carboxylic 
acid, hydroxyl, sulfhydryl and amino groups.
Proteins, including antibodies, generally have several 
primary amines in the side chain of lysine residues and the 
N-terminus of each polypeptide that are available as targets International Journal of Nanomedicine 2010:5 41
Nanotechnology methods used to combine proteins Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
for N-hydroxysuccinimide-ester and carbodiimide reagents. 
Cysteine residues on proteins can react with maleimides 
and iodoacetamides reagents to give thioether-coupled 
products.113 These reagents react rapidly at physiological pH 
and can be usually coupled with thiol groups selectively in the 
presence of amine groups. Maleimides and iodoacetamides 
have the same application but the first reagent seems to have 
better selectivity than the second one, not apparently reacting 
with histidine or methionine.
Cross-linking reagents contain reactive ends to specific 
functional groups (such as primary amines, sulfhydryls) 
on proteins or other molecules. They can be divided into 
homobifunctional (same reactive groups) and heterobifunctional 
(different reactive groups) which chemical cross-links may or 
may not be reversed.114 Homobifunctional cross-linkers have 
a disadvantage of potentially connecting two neighboring 
groups, either on the nanoparticle surface or on the protein 
inducing undesired cross-linking. Heterobifunctional 
crosslinkers allow sequential conjugations, minimizing 
polymerization. For example, sulfosuccinimidyl-4-(N-
maleimidomethyl)-cyclohexane-1-carboxylate (sulfo-SMCC) 
can be used to couple thiol-containing biomolecules with 
amine–coated nanoparticles, or vice versa. Whereas the hetero-
bifunctional cross-linker 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) is commonly used to link –NH2 and 
–COOH groups (Table 1).114–118
Many cross-linkers are available in the market and 
they can be chosen for specific needs (such as chemi-
cal specificity, spacer arm length, cleavability). Among 
several cross-linkers, the zero-length ones such as 
carbodiimides are widely used allowing covalent bonds 
between nanoparticles and proteins without insertion of 
an exogenous spacer. Nevertheless, the direct attachment 
of a protein to a surface without a spacer can cause steric 
constraint modifying the protein reactivity compared to the 
protein in solution. In addition, without a spacer, multiple 
contacts between protein and nanoparticle surface are more 
probable favoring total or partial protein denaturation and 
thus decreasing protein activity.119
When protein does not have the suitable residue necessary 
for the specific conjugation, the most common way to get it is 
the chemical introduction of sulfhydryl groups. This process 
(Figures 1a and 1b) can be mainly made by the following 
four methods: 1) reduction of protein disulfide bonds using 
reductive agents such as dithiotreitol (DTT = Clelands 
reagent). 2) Coupling of protein primary amino groups with 
2-iminothiolane (Trauts reagent). 3) Quenching of reactive 
protein aldehyde residues with cystaminiumdichloride 
reagents or 4) coupling of cystaminiumdichloride to carboxyl 
groups via 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide 
(EDC); both cases followed by the disulfide bonds reduction 
with DTT as outlined above.112,120–123
The avidin/streptavidin–biotin bound is the strongest 
noncovalent biological interaction known; for this reason this 
technology is commonly used in biological labs.124,125
Biotinylated proteins/antibodies/enzymes can be 
efficiently coupled on amino nanoparticle surfaces by 
streptavidin-biotin technology accomplished by streptavidin 
activation through carbodiimide (EDC) chemistry. Biotin 
binds strongly to this biochemically modified surface in the 
most specific and sensitive way. Furthermore, streptavidin 
through carbodiimide (EDC) chemistry can be covalently 
coupled with different ligands such as mAb and enzymes 
which make the biotin–streptavidin system widely used in a 
variety of biotinylated nanoparticles.38,126–128
Proteins having cysteine residues can be directly attached 
to some metal nanoparticle surfaces such as gold and silver 
by stable metal–sulfur bonds.129,130 In the other cases, the 
Table 1 The most popular cross-linker reagents for coupling protein to nanoparticle based on their respective functions
Reactive groups Eg of functional 
cross-linker
Functional groups on 
nanoparticles/proteins
Functional groups on 
proteins/nanoparticles
–NHS ester 
Maleimide or 
Iodoacetamides
SIAB, SMCC, SPDP, 
SPMB, MBS
–NH2 –SH
Carbodiimide eDC or eDAC + 
sulfo-NHS stabilizer
–COOH –NH2
–NHS ester eGS, DSP, DSS, BS3 –NH2 –NH2
Maleimide BMMe –SH –SH
Abbreviations: SIAB, N-succinimidyl(4-iodoacetyl)aminobenzoate; SMCC, succinimidyl-4-(N-maleimidomethyl)cyclohexana-1-carboxylate; MBS, m-maleimidobenzoyl-
N-hydroxysuccimide ester; SPDP, succinimidyl 3-(2-pyridyldithio)propionate; SPMB, succinimidyl (4-p-maleimidophenyl)butyrate; eDC, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride; eGS, ethylene glycolbis(succinimidylsuccinate); BS3, bis-(sulfosuccinimidyl) suberate; BMMe, bis(maleimido methyl) ether; DSS, disuccinimidyl 
suberate; DSP, dithiobis (succinimidyl propionate).International Journal of Nanomedicine 2010:5 42
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covalent coupling of proteins on nanoparticle surfaces is 
always a long experimental procedure.
Covalent bioconjugation procedure can be summarized in: 
1) Coating of nanoparticles with the selected active functional 
groups. 2) Chemical activation of thiol groups on the protein 
side with specific reductive agents, if necessary. 3) Total 
removal of the reduction agent in excess; this step can create 
unplanned reactions and spoil the whole coupling process. 
4) Post conjugation procedures such as removal of unbound 
protein/remnant excess.
In addition to the disadvantage of the long experimental 
procedure, covalent bioconjugation can affect the protein 
structure and function resulting in its partial denaturation 
(Figure 2). Moreover, modification of enzymes under strong 
Dithiotreitol (DTT)
(1)
COOH COOH
COOH
CHO
CHO
CHO
S-S
S-S
NH2
+
NH2
NH2
SH
SH
SH
NH
2- iminothiolane
(2)
Figure 1a The introduction of sulfhydryl groups by: 1) the reduction of protein disulfide bonds using reductive agents such as dithiotreitol (DTT = Cleland’s reagent). 2) Coupling 
protein primary amino groups with 2-iminothiolane (Traut; s reagent).
S-S
NH2 NH2
NH2
NH2
NH2
S-S
CHO
CHO
COOH
S-S
COOH
CHN-(CH2)2-S-S-(CH2)2-NH2
COHN-(CH2)2-S-S-(CH2)2-NH2
COHN-(CH2)2-S-H
CHN-(CH2)2-S-H
COOH Cystaminiumdichiloride
EDC
(4)
Dithiotreitol (DTT)
CHO
SH SH
SH SH
(3)
Cystaminiumdichloride
Dithiotreitol (DTT)
Figure 1b The introduction of sulfhydryl groups by: 3) Quenching of reactive protein aldehyde residues with cystaminiumdichloride reagents or 4) coupling of cystaminiumdichloride 
to carboxyl groups via 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide (EDC); both cases followed by the disulfide bonds reduction with DTT.International Journal of Nanomedicine 2010:5 43
Nanotechnology methods used to combine proteins Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
denaturing conditions can result in their complete loss of 
activity.
Proteins can be denaturated during manipulations or 
formulations mainly by two mechanisms: conformational 
denaturation (eg, reversible unfolding and irreversible 
aggregation via noncovalent interactions) and chemi-
cal denaturation (covalent bonds such as deamidation, 
hydrolysis, oxidation, β-elimination, incorrect disulfide 
formation, Maillard reaction, and transamidation).
Even if the first denaturation mechanism can happen 
during the nanoparticles bioconjugation process, the second 
one is often necessary to obtain high efficacy of the coupling. 
For example, the –SH or –S-groups in cysteine –SH or 
disulfide –S–S– bridges are important in maintaining the 
conformation of the proteins. As a result, the engineering 
introduction of sulfhydryl groups in the protein changes its 
natural disulfide bonds resulting in partial conformational 
and chemical denaturation.
The DTT reagent, widely used to reduce disulfide bonds 
in biochemical systems, can alter protein function not only 
by thiol-disulfide exchanging but also by interacting with 
protein domains in the absence of cysteine residues.131
While carboxyl groups seem to play an important role in 
enzymes catalytic activity,132 their modification likely results 
in a change of protein secondary and tertiary structure.
The ε-amino groups of lysine are often specifically targeted 
because of their high reactivity and their modification seems 
to have fewer effects on protein properties. Unfortunately, 
the high abundance of these groups in many proteins can 
lead to increased heterogeneity and restricted conformational 
flexibility owing to multipoint attachment on a nanoparticles 
surface.
It is also possible that other reagents used during the 
coupling chemical process can contribute to the protein 
denaturation and to its activity loss. Therefore biological 
function checking as well as close monitoring of the quality 
and quantity of conjugated protein are extremely important 
to be assessed before being used.111
Gold or silver nanoparticles too, due to the similar strength 
bond between Au/Ag–S and S–S, can potentially break up 
protein disulfide –S–S– bridges leading to denaturation.
Specific ELISA kits can be used to explore the activity 
of the proteins coupled to nanosystems. However there are 
nanoparticles such as quantum dots (QD) that can have an 
overlap in the absorption spectra and the ELISA essay end 
product. In this case the proper specific activity of the protein 
needs to be assessed directly by in vitro testing.133
Protein encapsulation
Therapeutic biomolecules based on peptides, proteins or 
enzymes can be extremely fragile and easily aggressed by 
external agent such as proteases. Encapsulation of these 
fragile drugs in nanocarriers is a possible strategy for pre-
venting their aggression and denaturation. This process can 
also improve the drug pharmacokinetic pathway and reduce 
immunological reactions.19
An optimal drug delivery system should be biocompatible, 
biodegradable and should not cause any immunological 
SPMB
(Heterobifunctional
protein crosslinker)
Size of nanomaterial:
Could affect the protein
folding
Nanomaterial:
Different affinity
for different
functional
groups
Target site: Could
affect protein stability
and activity
HN
HN
S
O
O
O
N
N
N
O
O
O
O
O
O
S
S
Figure 2 Protein–nanoparticle interactions: main factors that can affect proteins resulting in their denaturation. In this example, proteins are conjugated on amino functionalized 
nanoparticles using the cross-linker SPMB.International Journal of Nanomedicine 2010:5 44
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adverse reaction in the human body. Among several 
candidates, liposomes are considered as the most promising 
vectors for proteins delivery due to their biocompatibility 
and their capacity to improve the drug pharmacokinetic. 
Liposomes, also known as lipid-based vesicles, are 
generally composed of concentric amphiphilic lipids, 
such as phospholipids, containing a water compartment. 
These carriers are versatile and their physico–chemical 
characteristics can be properly tuned.19 Liposomes synthe-
sized from dehydrated–rehydrated vesicles are widely used 
due to the ease of this preparation process and the low amount 
of stress applied to the proteins.134
Liposome formulations are most frequently considered 
for parental administration of the drug, but may also be a 
potential formulation principle for alternative routes such 
as topical and nasal administration.
Several liposomes have immunoadjuvant properties and 
their application in vaccines based on recombinant protein 
subunits and synthetic–peptide antigens is attractive. The first 
liposome based vaccine (against hepatitis A) that has been 
licensed for human use is commercially known as Epaxal 
Berna® vaccine.135
The main drawback of liposomes is their instability 
in biological media as well as their sensitivity to many 
external parameters such as temperature or osmotic pressure. 
Theoretically, it could be possible to increase their stability 
following several strategies such as the polymerization 
of a two–dimensional network in the hydrophobic core 
of the membrane, coating the liposome with a polyelec-
trolyte shell or adding surface active polymers to form 
mixed vesicular structures.136–138 However, poor loading and 
partial protein/enzyme denaturation during the entrapment 
process can occur.
Another well established technique to encapsulate 
biological species such as enzymes, antibodies and other 
proteins in a functional state is based on the sol–gel 
chemistry method.139 Silica is indeed considered a very 
appealing material for drug delivery systems because it is 
relatively inexpensive, chemically inert, thermally stable, and 
biocompatible. Amorphous silica, used for decades as a food 
additive and for specific applications, is generally regarded 
as safe. Up until now, the FDA has not established if existing 
silica safety data can be applied to nanoscale forms of the 
material. In this approach, polypeptides, especially enzymes, 
could be entrapped inside silica matrix allowing the retention 
of enzymatic activity.139–141
On the other hand, process difficulties such as uncontrolled 
release, denaturation and the hardness control of the protein 
Silica
precursor
+ H2O
Sol solution
Gelatination
Wet-gel
H2O
Add enzyme
preparation, pH 7
Figure 3 entrapment of enzymes using sol-gel chemistry:   A schematic overview of the sol-gel process. Several silicate precursors can be used to modify the surface chemistry 
of the sol-gels such as TMSO,   APTeS, MTMOS, and eTMOS.
Abbreviations:  TMSO, tetramethyl orthosilicate;   APTeS, 3-aminopropyltriethoxysilane; MTMOS, methyltrimethoxysilane; eTMOS, ethyltrimethoxysilane.International Journal of Nanomedicine 2010:5 45
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orientation can be found.142,143 The control of the drug release 
of such silica nanoparticles is the most important and difficult 
parameter that needs to be properly tuned. The encapsulation 
efficacy of insoluble protein is greatly different compared to 
the soluble one and the existence of soluble and insoluble 
part of polypeptides in the same therapeutic protein subunit 
complicates the synthesis process. Additionally, in the 
crowded environment of a silica matrix, the physical and 
chemical properties of the silica can directly influence 
protein structure and activity. Furthermore, functional activity 
of proteins entrapped into the sol-gel matrix needs to be 
accurately analyzed case-by-case using several techniques 
such as CD spectropolarimetry.144,145
The drug release and the capability of the carrier to be 
metabolized can be important factors to be considered when 
chronic or repeated treatments are necessary. The disadvan-
tage associated with inorganic and synthetic carriers are the 
poor or slow biodegradability and possible inflammatory 
responses.146
Biodegradable polymers nanosystems are an attractive 
alternative to liposomes since they have the advantages of 
longer circulation in the blood stream and generally higher 
drug carrying capacity.147 Polymers such as poly(lactic 
acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) have 
been extensively investigated for their biocompatibility and 
potential capability of releasing therapeutically proteins in 
a controlled way even over a prolonged period of time.148–154 
These polymers are degradable by bulk erosion through 
hydrolysis of the ester bonds. The hydrolysis rate depends 
on several nanoparticles physicochemical parameters and 
can be tailored according to the desired release pattern of 
the protein to be incorporated.
PLA and PLGA are FDA-approved as excipients to 
achieve sustained release of the active ingredient. However, 
their application in protein delivery systems is often 
characterized by low entrapment efficiency, burst release, 
instability of encapsulated hydrophilic protein and partial pro-
tein release.155–158 To improve the performance of these poly-
mer nanoparticles, polysaccharides such as alginate (ALG) and 
chitosan (CS) could be applied.151,159 CS and its derivatives 
have been intensively studied as carriers for proteins and drugs. 
More specifically these nanoparticles can be totally made by 
CS or used in several copolymer combinations.25,160
Copolymers made by the combination of CS/ALG are 
able to generate a more “friendly” environment which 
protects peptides and proteins from stressing conditions and 
allows their stabilization during encapsulation, storage and 
release.161–166
Glycol chitosan nanoparticles modified with hydrophobic 
bile acid analogs self-assemble into polymeric nanoparticles 
with hydrophilic shells of glycol chitosan and hydrophobic 
cores of bile acid derivatives have been reported as possible 
vehicle for RGD (Arg–Gly–Asp) peptide.29,30
Regardless of the nanomaterial chosen for protein 
encapsulation, an important issue that needs to be considered 
is the understanding of protein–protein interactions. There 
are large numbers of transient protein–protein interactions 
that occur in the cell, which in turn control a large number 
of cellular processes. These transient interactions of protein 
complexes can cause several effects such as activation/
inactivation of certain proteins, resulting in the formation 
of a new binding site.167,168 Kinetics properties of enzymes 
can be also altered by denaturation during the entrapment 
process allowing potential change of the protein specificity 
to its substrate.169–171
Gaining a clear picture of these basics knowledge will 
definitely lead to a change of object design to increase the 
protein load, to control the protein release and to retain the 
protein integrity and efficacy.
Conclusion
Although new proteins are available for medical purposes, 
their administration as therapeutics still remains difficult. 
Nanosystems seem to be the optimal solution to improve 
protein bioavailability, biodistribution and safety. More-
over, the combination of nanoparticles with proteins could 
also be a valid system to achieve the design of efficient 
nanovectors for drug delivery. Indeed, nanoparticles can 
be properly tuned for specific applications and could be 
precisely designed to meet biological needs. However, 
to completely fulfill this purpose, it is necessary to better 
clarify the nature of interaction between nanoparticles and 
biomolecules. The control of the protein denaturation is 
another important parameter that needs a deeper under-
standing. Further investigations should help to manage 
these hybrid nanosystems, opening new therapeutic and 
diagnostic perspectives as well as new challenges in the 
near future.
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